Adjusted Chemotherapy According to Frailty Status in Elderly Patients With Diffuse Large B-Cell Lymphoma: Experience From a Single Referral Center in Mexico City

Lastra-German, Isabel K.; Navarrete‐Reyes, Ana Patricia; Mejía‐Domínguez, Nancy R.; Agreda-Vásquez, Gladys Patricia

doi:10.1016/j.clml.2018.11.013

Cited by 9 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both frailty (according to the Fried phenotype) and vulnerability (assessed by VES-13 and G8) were independently associated with an increased risk of chemotherapy toxicity. 65 Two other studies 66,67 from Latin America examined the role of a comprehensive geriatric assessment in patients with lymphoma. A study from Mexico analysed the role of frailty for adjusting chemotherapy dosing in 56 older people with diffuse large B-cell lymphoma (median age 70•5 years).…”

Section: Methods and Time Of Administrationmentioning

confidence: 99%

“…Adjusting chemotherapy according to frailty status allowed a group of unfit patients to tolerate treatment with good results. 66 Another study done in Peru compared different geriatric assessment tools in 253 older people with aggressive non-Hodgkin lymphomas. A locally developed tool, the Peruvian Abbreviated Comprehensive Geriatric Assessment, which included an evaluation of polypharmacy, physical function, instrumental activities of daily living, and social support, was shown to be superior to both VES-13 and G8 for detecting geriatric syndromes.…”

Section: Methods and Time Of Administrationmentioning

confidence: 99%

“…In 2020, of 32 abstracts that included at least one aspect of the geriatric assessment in patients with haematological malignancies presented at the annual American Society of Hematology and European Haematology Association meetings, only three included data from LMICs: one from Peru and two multicentre international clinical trials with patients from Brazil and Ukraine. [66][67][68][69][70][71]…”

Section: Methods and Time Of Administrationmentioning

confidence: 99%

See 2 more Smart Citations

Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings

Soto‐Pérez‐de‐Celis

Martínez-Peromingo²,

Chávarri‐Guerra³

et al. 2021

The Lancet Healthy Longevity

View full text Add to dashboard Cite

In 2020, about 600 000 people aged 65 years and older were diagnosed with a haematological malignancy worldwide, and this number will increase to almost 1 million by 2040, with the largest growth taking place in regions with less developed economies. Health-care systems globally are ill-prepared to face this impending increase in the burden of haematological malignancies among older people, and geriatric oncology and haematology are not properly developed in most low-income and middle-income countries, as well as in many community settings in high-income countries. Here, we provide an overview of the status of geriatric haematology in resource-limited settings, with a focus on health-care systems, educational activities, availability of resource-stratified guidelines, development of clinical programmes, and ongoing research initiatives. We also provide recommendations for the future development of geriatric haematology globally, focusing on the creation of educational activities for health-care providers, fostering research initiatives, improving the inclusion of principles of geriatric care into everyday clinical practice, and building strong international and local partnerships among organisations. Health-care systems in LMICs and burden of haematological malignanciesNon-communicable disease burden has been growing during the last five decades and, because of demographic

show abstract

Section: Methods and Time Of Administrationmentioning

confidence: 99%

Section: Methods and Time Of Administrationmentioning

confidence: 99%

Section: Methods and Time Of Administrationmentioning

confidence: 99%

See 1 more Smart Citation

Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings

Soto‐Pérez‐de‐Celis

Martínez-Peromingo²,

Chávarri‐Guerra³

et al. 2021

The Lancet Healthy Longevity

View full text Add to dashboard Cite

show abstract

“…The successful treatment of leukemia and lymphoma has still faces many challenges. Although chemotherapy has been the most widely applicable therapy for hematological malignancies [36], the emerging fields of cancer immunotherapy have shifted to antibody therapies, nowadays a number of monoclonal antibodies enabled cure various leukemia and lymphomas [37].…”

Section: Monoclonal Antibody Treatment Of Leukemia and Lymphoma In Rementioning

confidence: 99%

Development of Therapeutic Antibody Technology And Recent Perspectives For Leukemia-Lymphoma Treatment

Yirga¹,

Lin²,

Huang³

et al. 2019

J Leuk

View full text Add to dashboard Cite

Advancement of monoclonal antibodies (Mabs) to be accepted as a therapy has long history. This article describes the dramatic developmental trend of therapeutic antibody technology and their significant role for treatment of leukemia-lymphoma at the current time. The therapeutic Mab technology development from murine (mouse origin) to fully human resulted in low immunogenicity and high quality Mabs. Chemotherapy is standard care for leukemialymphoma treatments. However, it is associated with high toxicities (side effects), painful and relatively ineffective against certain leukemia-lymphoma subtypes. The remarkable contribution of Von Behring, Paul Ehrlich and the discovery of hybridoma technology marked the beginning of antibodies for therapeutic applications. Rituximab is the first Mab approved by Food and Drug Administration against B-cell malignancies. Today, a number of effective Mabs targeting leukemia and lymphoma were approved and successfully developed. The Mab therapeutic phenomena in the body (also called war in the blood) has various mechanism of actions. In recent years, Mab against leukemialymphoma achieved significantly therapeutic outcomes, eventually this led to traditional chemotherapy treatment free era. We also reviewed that, the therapeutic efficacy of Mabs against leukemia-lymphoma as compared antibody alone and antibody conjugated with potent chemotherapy or cytotoxic drugs. This article extends our understanding of advancements in therapeutic Mabs technology and provides new insights of Mab leukemia-lymphomas therapy. We also encourage further more studies for Mab based diagnostics, treatments of leukemia and lymphomas.

show abstract

“…The outcome of inpatient rehabilitation after hip fracture surgery may well be affected by frailty that pre-existed to hip fracture. It is assumed that frailty tools may help in guiding management decisions in patient care [6][7][8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Use of the Frailty Tools Fi Mds and Fi Rockwood to Predict Outcomes of Inpatient Rehabilitation after Proximal Hip Fracture

Naschitz¹

2021

JCRR

View full text Add to dashboard Cite

Background Among factors which affect the outcome of rehabilitation after hip fracture, the role of pre-fracture frailty has not been defined. Objective To assess the impact of frailty on rehabilitation outcome in elderly persons with proximal hip fracture. Setting Geriatric rehabilitation center. Design Retrospective observational study. Subjects Forty consecutive patients with proximal hip fracture. Methods The following parameters were calculated: FI-MDS frailty index, Rockwood Clinical Frailty Scale (FI Rockwood), Functional Independence Measure (FIM) on discharge, absolute functional gain (ΔFIM), length of stay (LOS), and FIM gain per day (ΔFIM/LOS). FIM discharge ≥90 and motor FIM discharge >58 indicated success in rehabilitation. Results There were 31 women and 9 men, mean age 80 years. The mean pre-fracture FI MDS was 10 points (SD 5.8) out of 58 possible, the mean FI Rockwood score was 3 (SD 1.7) out of 7 possible. The mean admission FIM was 76.6 (SD 16), the mean discharge FIM was 92.7 (SD 19.3), mean LOS 22.5 days (SD 9.7), mean ΔFIM/LOS 0.8 (SD 0.6). Pre-fracture frailty was associated with worse outcome of rehabilitation: FI MDS predicted discharge FIM ≥90 with OR 0.86, p 0.012; FI Rockwood predicted discharge FIM ≥90 with OR 0.68, p 0.027; FI MDS predicted discharge motor FIM >58 with OR 0.91, p 0.07; FI Rockwood predicted discharge motor FIM >58 with OR 0.71, p 0.027. Conclusions Though pre-fracture frailty correlated with FIM on discharge, neither frailty tool was specific enough to predict success in rehabilitation and the necessary length of rehabilitation. Translating frailty scores in tools adequate for clinical decision making remains an aim for future studies.

show abstract

Adjusted Chemotherapy According to Frailty Status in Elderly Patients With Diffuse Large B-Cell Lymphoma: Experience From a Single Referral Center in Mexico City

Cited by 9 publications

References 33 publications

Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings

Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings

Development of Therapeutic Antibody Technology And Recent Perspectives For Leukemia-Lymphoma Treatment

Use of the Frailty Tools Fi Mds and Fi Rockwood to Predict Outcomes of Inpatient Rehabilitation after Proximal Hip Fracture

Contact Info

Product

Resources

About